Literature DB >> 32527859

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease.

Eric R Henry1, Troy Cellmer2, Emily B Dunkelberger2, Belhu Metaferia2, James Hofrichter2, Quan Li2, David Ostrowski2, Rodolfo Ghirlando3, John M Louis2, Stéphane Moutereau4,5, Frédéric Galactéros5,6, Swee Lay Thein7, Pablo Bartolucci5,6, William A Eaton1.   

Abstract

The pathology of sickle cell disease is caused by polymerization of the abnormal hemoglobin S upon deoxygenation in the tissues to form fibers in red cells, causing them to deform and occlude the circulation. Drugs that allosterically shift the quaternary equilibrium from the polymerizing T quaternary structure to the nonpolymerizing R quaternary structure are now being developed. Here we update our understanding on the allosteric control of fiber formation at equilibrium by showing how the simplest extension of the classic quaternary two-state allosteric model of Monod, Wyman, and Changeux to include tertiary conformational changes provides a better quantitative description. We also show that if fiber formation is at equilibrium in vivo, the vast majority of cells in most tissues would contain fibers, indicating that it is unlikely that the disease would be survivable once the nonpolymerizing fetal hemoglobin has been replaced by adult hemoglobin S at about 1 y after birth. Calculations of sickling times, based on a recently discovered universal relation between the delay time prior to fiber formation and supersaturation, show that in vivo fiber formation is very far from equilibrium. Our analysis indicates that patients survive because the delay period allows the majority of cells to escape the small vessels of the tissues before fibers form. The enormous sensitivity of the duration of the delay period to intracellular hemoglobin composition also explains why sickle trait, the heterozygous condition, and the compound heterozygous condition of hemoglobin S with pancellular hereditary persistence of fetal hemoglobin are both relatively benign conditions.
Copyright © 2020 the Author(s). Published by PNAS.

Entities:  

Keywords:  polymerization; protein fibers; sickle cell

Year:  2020        PMID: 32527859     DOI: 10.1073/pnas.1922004117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

Authors:  Archana Shrestha; Mengna Chi; Kimberly Wagner; Astha Malik; Jennifer Korpik; Adam Drake; Keertik Fulzele; Sylvie Guichard; Punam Malik
Journal:  Blood Adv       Date:  2021-05-11

Review 2.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 3.  Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Authors:  Melissa Azul; Eudorah F Vital; Wilbur A Lam; David K Wood; Joan D Beckman
Journal:  Transl Res       Date:  2022-03-27       Impact factor: 10.171

4.  Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.

Authors:  Eric R Henry; Belhu Metaferia; Quan Li; Julia Harper; Robert B Best; Kristen E Glass; Troy Cellmer; Emily B Dunkelberger; Anna Conrey; Swee Lay Thein; H Franklin Bunn; William A Eaton
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

Review 5.  Sickle cell vaso-occlusion: The dialectic between red cells and white cells.

Authors:  Nicola Conran; Stephen H Embury
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

6.  Oxidation of Erythrocytes Enhance the Production of Reactive Species in the Presence of Artemisinins.

Authors:  Ioannis Tsamesidis; Pierre Pério; Antonella Pantaleo; Karine Reybier
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

7.  Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models.

Authors:  Naoya Uchida; Linhong Li; Tina Nassehi; Claire M Drysdale; Morgan Yapundich; Jackson Gamer; Juan J Haro-Mora; Selami Demirci; Alexis Leonard; Aylin C Bonifacino; Allen E Krouse; N Seth Linde; Cornell Allen; Madhusudan V Peshwa; Suk See De Ravin; Robert E Donahue; Harry L Malech; John F Tisdale
Journal:  Cell Rep Med       Date:  2021-04-20

8.  MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding.

Authors:  Eric R Henry; Julia Harper; Kristen E Glass; Belhu Metaferia; John M Louis; William A Eaton
Journal:  Biophys J       Date:  2021-04-29       Impact factor: 3.699

9.  Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.

Authors:  Belhu Metaferia; Troy Cellmer; Emily B Dunkelberger; Quan Li; Eric R Henry; James Hofrichter; Dwayne Staton; Matthew M Hsieh; Anna K Conrey; John F Tisdale; Arnab K Chatterjee; Swee Lay Thein; William A Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

Review 10.  Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease.

Authors:  William A Eaton
Journal:  Mol Aspects Med       Date:  2021-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.